Skip to main content

Treatment Clinical Trials for Osteosarcoma

Review the osteosarcoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-47 of 47

AOH1996 for the Treatment of Refractory Solid Tumors
Status: Active
Location: 2 locations
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Location: 2 locations
SJCARB7H3_41BBL for the Treatment of Newly Diagnosed Metastatic High-Risk Osteosarcoma after Standard Chemotherapy, 3CAR4OS Trial
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
DFMO Maintenance for the Treatment of Patients with Relapsed Ewing Sarcoma or Osteosarcoma
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Modified Donor Peripheral Blood Stem Cells in Combination with Zoledronic Acid for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory Solid Tumors
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Hypofractionated Radiation and Lymphodepleting Chemotherapy Followed by B7-H3-CAR T Cells for the Treatment of Pediatric Patients with Relapsed or Refractory Sarcomas
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Status: Active
Location: 2 locations
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Modified Immune Cells (Autologous iC9.GD2.CAR.IL-15 T cells) for Treating Patients with Relapsed or Refractory High Risk Neuroblastoma, Ganglioneuroblastoma, or Osteosarcoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Targeted IL12 T-cell Therapy for Treatment Advanced or Metastatic Soft Tissue or Bone Sarcomas
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Tumor Infiltrating Lymphocytes for the Treatment of Children with High Risk Solid Tumors
Status: Active
Location: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Upfront Surgical Resection for the Treatment of Localized High-Grade Osteosarcoma of the Extremity
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Status: Active
Location: See ClinicalTrials.gov
Evaluating Safe Methotrexate Blood Levels for Hospital Discharge in Newly Diagnosed Localized or Metastatic Osteosarcoma Patients Receiving High Dose Methotrexate, The CATSINDO Trial
Status: Approved
Location: 2 locations
Selumetinib and ZEN-3694 with Durvalumab for the Treatment of Sarcomas including Malignant Peripheral Nerve Sheath Tumors
Status: Approved
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Adaptive Proton Therapy to Improve Tumor Coverage for the Treatment of Children and Young Adults with Sarcomas, Bone and Soft Tissue Tumors or Hodgkin's Lymphoma
Status: Approved
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients with Newly Diagnosed Osteosarcoma
Status: Temporarily Closed to Accrual
Location: 181 locations
CD70 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Status: Temporarily Closed to Accrual
Location: UT MD Anderson Cancer Center, Houston, Texas
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults with Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial
Status: Temporarily Closed to Accrual
Location: 6 locations